Oncology

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Long term survival was limited and all patients with B-cell acute lymphoblastic leukemia eventually relapsed.

Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed different indications for the iNKT therapy AgenT-797.

The treated patient achieved an overall partial response of 72% in tumor regression.

ACE1831 will soon be evaluated in a phase 1, first-in-human, clinical trial.

Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.

The director of the Center for Multiple Myeloma at Mass Gen discussed current CAR T-cell therapies in multiple myeloma.

A multisite phase 1 clinical trial for NT-I7 is underway in patients with relapsed/refractory large B-cell lymphoma.

Review top news and interview highlights from the week ending June 17, 2022.

Jan ter Meulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, discussed the potential of the cytoDRIVE platform.

The therapy is now being evaluated in a phase 2 study.

CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).

The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed more work to be done with CAR T-cell therapies.

Mustang Bio presented data on MB-106 at the 2022 EHA Congress.

Among treated patients, 42% achieved 5-year event free survival.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

GC012F also showed efficacy in B-cell non-Hodgkin lymphoma.

The CD-19 CAR T-cell therapy is developed using Curocell’s OVISTM platform.

Response rates were significantly higher but patients had more cases of ICANS and CRS with axi-cel treatment compared to tisa-cel treatment.

Participants in the trial achieved a sustained response and experienced low-grade toxicity.

A phase 2 clinical trial evaluating a T-cell memory enriched anti-CD30 CAR-T is now underway.

As of the data cutoff, 3 of 5 treated participants remain in complete response.

Statistically significant differences were seen in global health status, pain, and fatigue.

Review top news and interview highlights from the week ending June 10, 2022.